For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 2,613 | 3,325* | 2,104 | 2,487 |
| General and administrative | 2,653 | 2,785* | 1,863 | 2,714 |
| Severance and related charges | - | 0* | 0 | - |
| Total operating expenses | 5,266 | 6,109* | 3,967 | 5,201 |
| Interest income | 176 | 91* | 113 | 107 |
| Loss from operations | -5,090 | -6,018 | -3,854 | -5,094 |
| Net loss | -5,090 | -6,018 | -3,854 | -5,094 |
| Basic EPS | -0.26 | -1.347 | -0.85 | -1.24 |
| Diluted EPS | -0.26 | -1.347 | -0.85 | -1.24 |
| Basic Average Shares | 19,467,114 | 4,466,148 | 4,537,683 | 4,119,153 |
| Diluted Average Shares | 19,467,114 | 4,466,148 | 4,537,683 | 4,119,153 |
IN8BIO, INC. (INAB)
IN8BIO, INC. (INAB)